Articles by James C. Greenwood - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by James C. Greenwood

James C. Greenwood

Jim Greenwood is president and CEO of the Biotechnology Industry Organization, 1201 Maryland Ave. SW, Suite 900, Washington, DC 20024, tel. 202.962.9200.

Prescribing Caution for Biosimilars
April 2, 2013

Sound policies are needed to govern the substitution of interchangeable biologics.

Intellectual Property as the Foundation of Innovation
December 2, 2010

Supportive public policy is needed in order for innovation to flourish.

Delivering on the Promise of Biotechnology
April 2, 2010

The BIO convention, and healthcare reform, could re-energize biotech.

Healthcare Reform Requires Room for Innovation
January 2, 2010

To move from R&D to breakthrough drugs, biotech companies need policies that support innovation.

Progress Made on the Path to Biosimilars
October 2, 2009

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.

Biotechnology in 2009
May 2, 2009

The president of BIO proposes the ingredients needed for industry growth.

Industry Leaders Debate Follow-on Biologics Pathway
May 2, 2009

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
FindPharma Custom Search
Click here